A Phase I Bridging Study to Evaluate the PK, PD, Safety and Tolerability of SR1375 in Healthy Subjects
Latest Information Update: 02 Dec 2024
At a glance
- Drugs SR 1375 (Primary)
- Indications Diabetic macular oedema
- Focus Pharmacokinetics
- Sponsors SIMR Biotech
- 08 Feb 2023 Status changed from active, no longer recruiting to completed.
- 12 Dec 2022 Planned End Date changed from 30 Oct 2022 to 30 Mar 2023.
- 12 Dec 2022 Planned primary completion date changed from 30 Sep 2022 to 17 Jan 2023.